- ADMA Biologics recently reported a mixed Q4/2020 earnings with a slight miss on EPS and a slight beat on revenue. Consequently, ADMA has been under substantial selling pressure.
- The ongoing pandemic has disrupted the industry; however, ADMA was able to report record revenue and expects to report quarter-over-quarter revenue growth.
- ADMA has updated their BioCenter construction guidance from constructing 5-10 facilities by 2024 to 10+ facilities by 2024. In addition, the company believes they will be profitable by Q1 of 2024.
- I have been adding aggressively during this sell-off in anticipation that my current ADMA strategy will pay off. I discuss my strategy and my long-term plan.
For further details see:
ADMA Biologics: Sell-Off Provides Buying Opportunity Ahead Of Projected Growth